Document is current
Any future updates will be listed below
-
Authors
Seyedshahi, Farzaneh https://orcid.org/0009-0007-1111-052X
Rakovic, Kai https://orcid.org/0000-0002-0676-1973
Poulain, Nicolas
Claudio Quiros, Adalberto
Powley, Ian R. https://orcid.org/0009-0009-6079-6673
Richards, Cathy
Uraiby, Hussein
Klebe, Sonja https://orcid.org/0000-0002-8976-4714
Moore, David A. https://orcid.org/0000-0002-6296-1312
Nakas, Apostolos
Wilson, Claire R. https://orcid.org/0000-0002-6401-2014
Sereno, Marco https://orcid.org/0000-0003-4573-9303
Officer-Jones, Leah https://orcid.org/0000-0002-3690-2386
Ficken, Catherine
Teodosio, Ana
Ballantyne, Fiona
Murphy, Daniel https://orcid.org/0000-0002-5538-5468
Yuan, Ke https://orcid.org/0000-0002-2318-1460
Le Quesne, John https://orcid.org/0000-0003-3552-7446
-
Funding
Funding for this research was provided by:
Cancer Research UK (EDDPGM-Nov21\100001)
- License Information
-
More Information
Article History
Received: 5 January 2025
Accepted: 29 August 2025
First Online: 7 October 2025
Competing interests
: D.A.M. has received speaker fees from AstraZeneca, Eli Lilly, BMS, Takeda and Boehringer Ingelheim; consultancy fees from AstraZeneca, ThermoFisher, Takeda, Amgen, Janssen, MIM software, Bristol-Myers Squibb and Eli Lilly; and educational support from Takeda and Amgen. All other authors declare no competing interests.
